Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 11:54 PM
Ignite Modification Date:
2025-12-25 @ 9:50 PM
NCT ID:
NCT03532451
Group ID:
EG001
Title:
Cohort 2: Nivolumab/Lirilumab
Description:
Nivolumab 480 mg IV and Lirilumab 240 mg on week 0 and week 4
Nivolumab/Lirilumab: Nivolumab 480 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) with at least a 30 minute rest between infusions followed by lirilumab 240 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
Deaths Number Affected:
6
Deaths Number At Risk:
None
Serious Number Affected:
6
Serious Number At Risk:
29
Other Number Affected:
28
Other Number At Risk:
29
Study:
NCT03532451
Results Section:
NCT03532451
Adverse Events Module:
NCT03532451